Secondly, in non-operable NSCLC patients with no EGFR or ALK genomic tumor aberrations, first-generation PD-1/PD-L1 inhibitors, either as monotherapy or in combination with platinum-containing combination chemotherapy, has become the standard of care first line treatment. The gene discussed is ALK; the disease is neoplasm.